Zobrazeno 31 - 40
of 112
pro vyhledávání: '"Suk-Young Yoo"'
Autor:
Alexander J Stratigos, Aleksandar Sekulic, Ketty Peris, Oliver Bechter, Sorilla Prey, Martin Kaatz, Karl D Lewis, Nicole Basset-Seguin, Anne Lynn S Chang, Stéphane Dalle, Almudena Fernandez Orland, Lisa Licitra, Caroline Robert, Claas Ulrich, Axel Hauschild, Michael R Migden, Reinhard Dummer, Suk-Young Yoo, Ebony Coates, Emmanuel Okoye, Ioannis Bassukas, Carmen Loquai, Vincenzo De Giorgi, Zeynep Eroglu, Ralf Gutzmer, Jens Ulrich, Susana Puig, Frank Seebach, Israel Lowy, Matthew G Fury
Publikováno v:
SKIN The Journal of Cutaneous Medicine. 7:s178
Autor:
Brett Hughes, Jean-Jacques Grob, Samantha Bowyer, Fiona Day, Rahul Ladwa, Brian Stein, Eva Muñoz-Couselo, Nicole Basset-Seguin, Alexander Guminski, Laurent Mortier, Axel Hauschild, Michael Migden, Chrysalyne Schmults, Suk-Young Yoo, Jocelyn Booth, Frank Seebach, Israel Lowy, Matthew Fury, Danny Rischin
Publikováno v:
SKIN The Journal of Cutaneous Medicine. 7:s175
Autor:
Israel Lowy, N. Alice Yama-Dang, Jingjin Li, June Y. Hou, Suk Young Yoo, Kyriakos P. Papadopoulos, Danny Rischin, Joaquina Baranda, Antonio González-Martín, M. Feng, Daniel Cho, Melissa Mathias, Silvia C. Formenti, Marta Gil-Martin, Wen Fury, Gerald Steven Falchook, Kathleen N. Moore, Salma K. Jabbour, Aung Naing, Irene Brana, Matthew G. Fury, Elizabeth Stankevich
Publikováno v:
Scientia
Cemiplimab; Càncer de coll uterí metastàtic; Càncer de coll uterí recurrent Cemiplimab; Cáncer de cuello uterino metastásico; Cáncer de cuello uterino recurrente Cemiplimab; Metastatic cervical cancer; Recurrent cervical cancer Objectives To
Autor:
Matthew G. Fury, Siyu Li, Medha Sasane, Dirk Schadendorf, Nikhil I. Khushalani, Karl D. Lewis, Vera Mastey, Elizabeth Stankevich, Axel Hauschild, Jocelyn Booth, Michael R. Migden, Anne Lynn S. Chang, Suk Young Yoo, Chieh I. Chen, Leonel Hernandez-Aya, Emmanuel Okoye, Zhen Chen, Chrysalyne D. Schmults, Israel Lowy, Alexander Guminski, Brett G.M. Hughes, Danny Rischin, Alesha A. Thai, Annette M. Lim
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 8 (2021)
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 8 (2021)
BackgroundTo provide pooled longer term data from three groups of a phase 2 study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (CSCC), and to determine duration of response (DOR) and impact on quality of life (QoL).Method
Publikováno v:
Gynecologic Oncology. 166:S282
Autor:
Karl Lewis, Ketty Peris, Aleksander Sekulic, Alexander J. Stratigos, Lara Dunn, Zeynep Eroglu, Anne Lynn S. Chang, Michael R. Migden, Suk-Young Yoo, Kosalai Mohan, Ebony Coates, Emmanuel Okoye, Timothy Bowler, Jean-François Baurain, Oliver Bechter, Axel Hauschild, Marcus O. Butler, Leonel Hernandez-Aya, Lisa Licitra, Rogerio I. Neves, Emily S. Ruiz, Frank Seebach, David M. Weinreich, George D. Yancopoulos, Israel Lowy, Priscila Goncalves, Matthew G. Fury
Publikováno v:
Cancer Research. 82:CT165-CT165
Background: Cemiplimab is the first treatment approved in the US (as cemiplimab-rwlc) for patients with metastatic basal cell carcinoma (mBCC) or locally advanced disease (laBCC) after hedgehog inhibitor (HHI) treatment or for whom an HHI is not appr
Autor:
Yihua Qiu, Kevin R. Coombes, A. Y. Raybon, Andrew Ligeralde, Chenyue Wendy Hu, Steve Kornblau, Suk-Young Yoo, Amina A. Qutub
Publikováno v:
Nature biomedical engineering
Acute myelogenous leukaemia (AML) is associated with risk factors that are largely unknown and with a heterogeneous response to treatment. Here, we provide a comprehensive quantitative understanding of AML proteomic heterogeneities and hallmarks by u
Autor:
Kyriakos P. Papadopoulos, Matthew G. Fury, P. Rietschel, Kosalai Kal Mohan, Elizabeth Stankevich, Pilar Garrido, Marta Gil-Martin, Suk-Young Yoo, Victor Moreno, Maria Jose De Miguel Luken, Lee S. Rosen, Israel Lowy, Raid Aljumaily
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 155
Objectives Blockade of programmed cell death-1 (PD-1) and its ligand (PD-L1) has transformed the treatment of NSCLC. In a first-in-human, Phase 1, dose escalation and cohort expansion study, cemiplimab, a monoclonal antibody directed against PD-1, wa
Autor:
Michael R. Migden, Axel Hauschild, Ralf Gutzmer, Suk Young Yoo, Nathalie Fiaschi, Matthew G. Fury, Jens Ulrich, Karl D. Lewis, Reinhard Dummer, Susana Puig, Anne Lynn S. Chang, Vincenzo De Giorgi, Claas Ulrich, Nicole Basset-Seguin, Almudena Fernandez Orland, Lisa Licitra, Sorilla Prey, Emmanuel Okoye, David M. Weinreich, Ketty Peris, Israel Lowy, Ebony Coates, Stéphane Dalle, Timothy Bowler, Martin Kaatz, George D. Yancopoulos, Caroline Robert, Frank Seebach, Siyu Li, Zeynep Eroglu, Vladimir Jankovic, Carmen Loquai, Oliver Bechter, Kosalai Kal Mohan, Gavin Thurston, Aleksandar Sekulic, Ioannis D. Bassukas, Alexander J. Stratigos
Publikováno v:
The Lancet. Oncology. 22(6)
Summary Background Before February, 2021, there was no standard treatment regimen for locally advanced basal cell carcinoma after first-line hedgehog inhibitor (HHI) therapy. Cemiplimab, a PD-1 antibody, is approved for treatment of advanced cutaneou
Autor:
Suk Young Yoo, Terzah M. Horton, Amina A. Qutub, Fieke W Hoff, Yihua Qiu, Michael E. Scheurer, Chenyue W. Hu, Eveline S. J. M. de Bont, Andrew Ligeralde, Steven M. Kornblau
Publikováno v:
Molecular Cancer Research, 16(8), 1263-1274. American Association for Cancer Research Inc.
Pediatric acute lymphoblastic leukemia (ALL) is the most common pediatric malignancy, and the second leading cause of pediatric cancer–related death in developed countries. While the cure rate for newly diagnosed ALL is excellent, the genetic heter